Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KDNYNASDAQ:NUVLNASDAQ:PLRXNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKDNYChinook Therapeutics$40.39$39.86$18.34▼$40.51$2.90B0.341.19 million shsN/ANUVLNuvalent$73.63+5.4%$71.44$55.54▼$113.51$5.27B1.42486,473 shs534,558 shsPLRXPliant Therapeutics$1.47+4.3%$1.47$1.10▼$16.52$90.24M1.431.07 million shs753,848 shsVRNAVerona Pharma$67.53+6.6%$63.25$11.39▼$74.18$5.48B0.21.28 million shs1.43 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKDNYChinook Therapeutics0.00%0.00%0.00%0.00%0.00%NUVLNuvalent+5.41%-2.39%+11.07%-11.18%+12.45%PLRXPliant Therapeutics+4.26%-7.55%+9.70%-43.68%-89.36%VRNAVerona Pharma+6.58%-6.53%+17.02%+13.82%+354.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKDNYChinook TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANUVLNuvalent2.0526 of 5 stars3.50.00.00.03.53.30.0PLRXPliant Therapeutics4.3065 of 5 stars4.02.00.04.72.61.70.6VRNAVerona Pharma3.0967 of 5 stars3.63.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKDNYChinook Therapeutics 0.00N/AN/AN/ANUVLNuvalent 2.90Moderate Buy$115.5056.87% UpsidePLRXPliant Therapeutics 2.00Hold$13.31805.61% UpsideVRNAVerona Pharma 3.11Buy$81.5020.69% UpsideCurrent Analyst Ratings BreakdownLatest NUVL, KDNY, VRNA, and PLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.004/30/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.004/28/2025VRNAVerona PharmaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy4/28/2025VRNAVerona PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$100.004/21/2025VRNAVerona PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$80.003/18/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/14/2025NUVLNuvalentUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$100.00 ➝ $100.003/4/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $1.503/4/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/4/2025PLRXPliant TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $3.003/4/2025PLRXPliant TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKDNYChinook Therapeutics$6.13M473.15N/AN/A$6.91 per share5.85NUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/APLRXPliant Therapeutics$1.58M57.11N/AN/A$7.91 per share0.19VRNAVerona Pharma$118.54M46.19N/AN/A$3.10 per share21.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKDNYChinook Therapeutics-$187.87M-$3.52N/AN/AN/A-4,199.93%-58.28%-44.72%N/ANUVLNuvalent-$126.22M-$4.39N/AN/AN/AN/A-28.63%-27.15%N/APLRXPliant Therapeutics-$161.34M-$3.47N/AN/AN/AN/A-48.91%-41.09%N/AVRNAVerona Pharma-$54.37M-$2.00N/A2,251.00N/AN/A-79.54%-43.49%N/ALatest NUVL, KDNY, VRNA, and PLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A4/29/2025Q1 2025VRNAVerona Pharma-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million3/3/2025Q4 2024PLRXPliant Therapeutics-$0.99-$0.82+$0.17-$0.82$0.08 millionN/A2/27/2025Q4 2024NUVLNuvalent-$1.03-$1.05-$0.02-$1.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKDNYChinook TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKDNYChinook TherapeuticsN/A5.825.82NUVLNuvalentN/A23.0723.07PLRXPliant Therapeutics0.0910.2610.26VRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKDNYChinook Therapeutics95.15%NUVLNuvalent97.26%PLRXPliant Therapeutics97.30%VRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipKDNYChinook Therapeutics16.79%NUVLNuvalent12.52%PLRXPliant Therapeutics8.00%VRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKDNYChinook Therapeutics21471.81 million59.75 millionOptionableNUVLNuvalent4071.60 million62.16 millionOptionablePLRXPliant Therapeutics9061.39 million56.96 millionOptionableVRNAVerona Pharma3081.08 million76.10 millionOptionableNUVL, KDNY, VRNA, and PLRX HeadlinesRecent News About These CompaniesFred Alger Management LLC Takes $1.34 Million Position in Verona Pharma plc (NASDAQ:VRNA)May 13 at 6:03 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Acquired by Barclays PLCMay 13 at 3:20 AM | marketbeat.comFindell Capital Management LLC Makes New $8.36 Million Investment in Verona Pharma plc (NASDAQ:VRNA)May 11 at 7:37 AM | marketbeat.comThe Manufacturers Life Insurance Company Has $5.89 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)May 10 at 4:20 AM | marketbeat.comDeep Track Capital LP Sells 2,330,025 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comDuquesne Family Office LLC Purchases 201,535 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Insider Sells $1,014,158.88 in StockMay 9, 2025 | insidertrades.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | insidermonkey.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | msn.comCaxton Associates LP Acquires New Position in Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comBeverly Hills Private Wealth LLC Purchases Shares of 5,566 Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comAxa S.A. Sells 74,142 Shares of Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comVerona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025May 7, 2025 | nasdaq.comVerona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025May 7, 2025 | nasdaq.comBellevue Group AG Trims Holdings in Verona Pharma plc (NASDAQ:VRNA)May 6, 2025 | marketbeat.comVerona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025May 6, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Increases Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)May 6, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Sees Large Decline in Short InterestMay 5, 2025 | marketbeat.comVoya Investment Management LLC Has $2.77 Million Position in Verona Pharma plc (NASDAQ:VRNA)May 5, 2025 | marketbeat.comHC Wainwright Boosts Earnings Estimates for Verona PharmaMay 4, 2025 | marketbeat.comQ2 EPS Estimates for Verona Pharma Cut by Roth CapitalMay 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNUVL, KDNY, VRNA, and PLRX Company DescriptionsChinook Therapeutics NASDAQ:KDNYChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Nuvalent NASDAQ:NUVL$73.63 +3.78 (+5.41%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$74.20 +0.57 (+0.77%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Pliant Therapeutics NASDAQ:PLRX$1.47 +0.06 (+4.26%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.54 +0.06 (+4.42%) As of 06:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Verona Pharma NASDAQ:VRNA$67.53 +4.21 (+6.65%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$66.72 -0.81 (-1.21%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
